termsTerm
Late recurrence
Hormone-driven breast cancer can come back 10 or even 20 years after treatment, unlike most cancers, which is why hormone therapy lasts so long.
About half of recurrences in HR+ disease occur after year 5; risk continues at 1-2% per year to year 20 (EBCTCG, Pan 2017), driven by tumour size and nodal status. Motivates extended endocrine therapy (ATLAS, aTTom, MA.17), adjuvant CDK4/6 inhibitors for high-risk disease, and research into dormancy, ctDNA surveillance, and late-recurrence prediction assays (Breast Cancer Index).
Clinical: what this kind of term is about · animated schematic, not to scale
Category
Clinical
cancers
2technologies
1pathways
2terms
1ideas
7Block the recycling that keeps dormant cells aliveBlunt the inflammation that wakes sleeping cancer cellsIntercepting late recurrence with ctDNA surveillance and oral SERDsKeep dormant cells asleep instead of trying to kill themKeep them asleep: dormancy maintenance as adjuvant therapyUse residual disease tests to decide who needs ten years of hormone therapyWhat decides which disseminated cells ever colonise?